01942nas a2200385 4500000000100000008004100001260001300042653001500055653001000070653000900080653001600089653001200105653003000117653001100147653001100158653002300169653001200192653000900204653001600213653001000229653002600239653001300265653002200278100001500300700001500315700001300330700001400343245015900357856005100516300001000567490000700577050003200584520092600616022001401542 2008 d c2008 Dec 10 aAdolescent 10 aAdult 10 aAged 10 aClofazimine 10 aDapsone 10 aDrug Therapy, Combination 10 aFemale 10 aHumans 10 aLeprostatic Agents 10 aleprosy 10 aMale 10 aMiddle Aged 10 aNepal 10 aRetrospective Studies 10 aRifampin 10 aTreatment Outcome 1 aSapkota BR 1 aShrestha K 1 aPandey B 1 aWalker SL 00 aA retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone. uhttps://leprosyreview.org/article/79/4/42-5428 a425-8 0 v79 aInfolep Library - available 3 aINTRODUCTION: Dapsone Hypersensitivity Syndrome (DHS) occurs in approximately 2% of leprosy patients in Nepal. DHS and other adverse effects of dapsone lead to withdrawal of the drug.
METHODS: We reviewed the notes of patients who had dapsone withdrawn from their multi-drug therapy (MDT) following an adverse reaction to the drug between 1990 and 2007.
RESULTS: 105 patients were identified from the database and 67 had a documented completion of a modified course of MDT. The majority were treated with rifampicin and clofazimine. All 36 individuals who were slit-skin smear positive had a satisfactory fall in their mean bacterial index. There were no cases of relapse.
CONCLUSIONS: Rifampicin and clofazimine appear to be satisfactory treatment for both paucibacillary and multibacillary patients who have to have dapsone stopped because of severe adverse effects.
a0305-7518